* Dare Bioscience Inc DARE.OQ DARE.O is expected to show
a
rise in quarterly revenue when it reports results on November
10.
* The San Diego California-based company is expected to
report
revenue of $1.99 million, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Dare Bioscience Inc
is
for a loss of 12 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Dare
Bioscience
Inc is $4, above its last closing price of $0.93.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.06 -0.06 0.00 Beat 100
Mar. 31 2022 -0.14 -0.14 -0.10 Beat 29.8
Dec. 31 2021 -0.20 -0.15 -0.18 Missed -23.3
Sep. 30 2021 -0.08 -0.13 -0.18 Missed -35.8
Jun. -0.16 -0.16 -0.18 Missed -14.3
30 2021
Mar. 31 2021 -0.27 -0.22 -0.17 Beat 23.6
Dec. 31 2020 -0.16 -0.13 -0.28 Missed -122.2
Sep. 30 2020 -0.19 -0.17 -0.24 Missed -41.2
This summary was machine generated November 8 at 16:12 GMT. All
figures in US dollars unless otherwise stated